{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:35:53Z","timestamp":1791722153011,"version":"4.3.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3J1291~2, CMRPG3H1711, CMRPG3K1921"],"award-info":[{"award-number":["CMRPG3J1291~2, CMRPG3H1711, CMRPG3K1921"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To investigate the value of serum adropin in predicting chronic kidney disease (CKD) progression in subjects with type 2 diabetes (T2D).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Serum adropin levels were measured in normal control and T2D patients with various stage of CKD. CKD progression was defined as \u2265 30% decline from the baseline estimated glomerular filtration rate. Logistic regression analysis was applied to assess the association between adropin levels and CKD progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 58 subjects with T2D (18 early CKD and 40 advanced CKD) and 9 subjects without diabetes (control). Subjects with T2D had significantly higher adropin levels than controls (6393.10 \u00b1 1611.84 vs. 3470.30 \u00b1 1284.41 pg\/ml; <jats:italic>P<\/jats:italic> &amp;lt; 0.001). Meanwhile, T2D patients with advanced CKD had higher adropin levels than those with early CKD (6848.89 \u00b1 1287.04 vs. 5380.25 \u00b1 1826.44 pg\/ml; <jats:italic>P<\/jats:italic> = 0.003). Among T2D patients, subjects experienced CKD progression had higher adropin levels than those without (7520.15 \u00b1 843.21 vs. 6151.16 \u00b1 1661.61 pg\/mL, <jats:italic>P<\/jats:italic> =0.003). Thus, adropin predicts CKD progression in T2D patients with 86% sensitivity and 70% specificity at 6872.24 pg\/ml cutoff value. The association with CKD progression was still significant after adjusting for age, gender and body mass index (adjusted odds ratio = 27.188, 95% confidence interval 1.415-522.527, <jats:italic>P<\/jats:italic> =0.029).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The above findings suggest that serum adropin could be applied as a potential biomarker for predicting CKD progression in subjects with T2D. Further research is needed to validate these results and explore the underlying mechanisms.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1511730","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:10:55Z","timestamp":1738905055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression"],"prefix":"10.3389","volume":"16","author":[{"given":"I-Wen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ni","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Tah","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease","volume":"21","author":"Palsson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta9300","article-title":"Systematic review on urine albumin testing for early detection of diabetic complications","volume":"9","author":"Newman","year":"2005","journal-title":"Health Technol Assess"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.0602","article-title":"Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review","volume":"313","author":"Levey","year":"2015","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4239\/wjd.v7.i14.290","article-title":"Early detection of diabetic kidney disease: Present limitations and future perspectives","volume":"7","author":"Lin","year":"2016","journal-title":"World J Diabetes"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.kisu.2017.10.003","article-title":"Diagnosis of diabetic kidney disease: state of the art and future perspective","volume":"8","author":"Persson","year":"2018","journal-title":"Kidney Int Suppl (2011)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.10.011","article-title":"Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism","volume":"8","author":"Kumar","year":"2008","journal-title":"Cell Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2194","article-title":"Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans","volume":"97","author":"Butler","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12902-023-01327-0","article-title":"Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies","volume":"23","author":"Soltani","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4149\/bll_2016_020","article-title":"Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats","volume":"116","author":"Akcilar","year":"2016","journal-title":"Bratislava Med J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.15412\/j.jbtw.01050301","article-title":"Elevated serum levels of adropin in patients with type 2 diabetes mellitus and its association with insulin resistance","volume":"5","author":"Hosseini","year":"2016","journal-title":"J Biol Today\u2019s World"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2019.1684951","article-title":"Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case-control study from Isfahan, Iran","volume":"128","author":"Palizban","year":"2022","journal-title":"Arch Physiol Biochem"},{"key":"B13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11010-013-1660-4","article-title":"Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes","volume":"380","author":"Aydin","year":"2013","journal-title":"Mol Cell Biochem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and european medicines agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.31","article-title":"Adropin deficiency is associated with increased adiposity and insulin resistance","volume":"20","author":"Ganesh Kumar","year":"2012","journal-title":"Obes (Silver Spring)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6038261","article-title":"Association of serum adropin concentrations with diabetic nephropathy","volume":"2016","author":"Hu","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000519173","article-title":"The clinical value of serum adropin level in early detection of diabetic nephropathy","volume":"46","author":"Es-Haghi","year":"2021","journal-title":"Kidney Blood Press Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.37.EP446","article-title":"Microalbuminuria by concentration serum and urine levels of adropin in patients with type 2 diabetes mellitus","author":"Ugur","year":"2015","journal-title":"Endocrine Abstracts"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/75944","article-title":"ENHO gene expression and serum adropin level in rheumatoid arthritis and systemic lupus erythematosus","volume":"27","author":"Yolbas","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/life12020169","article-title":"Serum adropin levels in patients with rheumatoid arthritis","volume":"12","author":"Simac","year":"2022","journal-title":"Life (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3266-1","article-title":"Serum adropin level and ENHO gene expression in systemic sclerosis","volume":"35","author":"Yolbas","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"C31","DOI":"10.1016\/j.jacc.2015.06.1146","article-title":"GW26-e1596 Effects of atorvastatin on mRNA and protein expression of adropin in cultured human umbilical endothelial cells and rat artery smooth muscle cells","volume":"66","author":"Zhao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.5163","article-title":"Elevated plasma levels of adropin in heart failure patients","volume":"50","author":"Lian","year":"2011","journal-title":"Intern Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7754\/clin.lab.2015.150420","article-title":"The effects of valsartan and amlodipine on the levels of irisin, adropin, and perilipin","volume":"61","author":"Celik","year":"2015","journal-title":"Clin Lab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020457","article-title":"The impact of SGLT2 inhibitor dapagliflozin on adropin serum levels in men and women with type 2 diabetes mellitus and chronic heart failure","volume":"11","author":"Berezin","year":"2023","journal-title":"Biomedicines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.fshw.2022.06.002","article-title":"Adropin as an indicator of T2DM and its complications","volume":"11","author":"Zhang","year":"2022","journal-title":"Food Sci Hum Wellness"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.362","article-title":"Adropin deficiency worsens HFD-induced metabolic defects","volume":"8","author":"Chen","year":"2017","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.931782","article-title":"Adropin is a novel regulator of endothelial function","volume":"122","author":"Lovren","year":"2010","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.3390\/jcm12062231","article-title":"Adropin predicts chronic kidney disease in type 2 diabetes mellitus patients with chronic heart failure","volume":"12","author":"Berezina","year":"2023","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.crphys.2022.01.005","article-title":"Diet-induced obese mice are resistant to improvements in cardiac function resulting from short-term adropin treatment","volume":"5","author":"Thapa","year":"2022","journal-title":"Curr Res Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S243755","article-title":"Promotion of adropin expression by hyperglycemia is associated with STAT3 activation in diabetic rats","volume":"13","author":"Kuo","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.04.023","article-title":"Chronic inflammation in chronic kidney disease progression: role of nrf2","volume":"6","author":"Stenvinkel","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3390\/ijms24076053","article-title":"Insights into the molecular mechanisms of NRF2 in kidney injury and diseases","volume":"24","author":"Lin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/antiox11061112","article-title":"Nrf2 activation in chronic kidney disease: promises and pitfalls","volume":"11","author":"Aranda-Rivera","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0829","article-title":"Is there a sweet spot for Nrf2 activation in the treatment of diabetic kidney disease","volume":"63","author":"Hall","year":"2014","journal-title":"Diabetes"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101068","article-title":"Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity","volume":"21","author":"Chen","year":"2019","journal-title":"Redox Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/antiox12040932","article-title":"Nrf2 protein serum concentration in human CKD shows a biphasic behavior","volume":"12","author":"Rasmussen","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003929","article-title":"Role of kidney function on Nrf2 mRNA levels in type 2 diabetes","volume":"12","author":"Spoto","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3109\/10520295.2013.821713","article-title":"Immunohistochemical expressions of adropin and inducible nitric oxide synthase in renal tissues of rats with streptozotocin-induced experimental diabetes","volume":"89","author":"Kuloglu","year":"2014","journal-title":"Biotech Histochem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00511.2015","article-title":"Adropin acts in brain to inhibit water drinking: potential interaction with the orphan G protein-coupled receptor, GPR19","volume":"310","author":"Stein","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00517.2016","article-title":"Adropin acts in the rat paraventricular nucleus to influence neuronal excitability","volume":"312","author":"Loewen","year":"2017","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169137","article-title":"Increased serum sodium and serum osmolarity are independent risk factors for developing chronic kidney disease; 5 year cohort study","volume":"12","author":"Kuwabara","year":"2017","journal-title":"PloS One"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1511730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:10:58Z","timestamp":1738905058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1511730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":43,"alternative-id":["10.3389\/fendo.2025.1511730"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1511730","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"article-number":"1511730"}}